OA07-04 LB. Immunogenicity of ALVAC-HIV® (vCP1521) and AIDSVAX® B/E prime boose vaccination in RV144, the Thai Phase III HIV vaccine trial

by Francis D, Tartaglia J, Rerks-Ngam S, Dally L, Nitayaphan S, Ratto-Kim S, Jongrakthaitae S, Phuang-ngem Y, Chuenarom W, Schuetz A, Trichavaroj R, de Souza MS, Michael NL, Paris RM, Kim JH
Published 2009-10-01

Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activation.

by Alexandra Schuetz, Claire Deleage, Irini Sereti, Rungsun Rerknimitr, Nittaya Phanuphak, Yuwadee Phuang-Ngern, Jacob D Estes, Netanya G Sandler, Suchada Sukhumvittaya, Mary Marovich, Surat Jongrakthaitae, Siriwat Akapirat, James L K Fletscher, Eugene Kroon, Robin Dewar, Rapee Trichavaroj, Nitiya Chomchey, Daniel C Douek, Robert J O Connell, Viseth Ngauy, Merlin L Robb, Praphan Phanuphak, Nelson L Michael, Jean-Louis Excler, Jerome H Kim, Mark S de Souza, Jintanat Ananworanich, RV254/SEARCH 010 and RV304/SEARCH 013 Study Groups
Published 2014-12-01